Analyst Research

Report Title Price
Provider: ValuEngine, Inc.
$49.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Ligand Pharmaceuticals Inc raises FY 2014 outlook; gives Q3 2014 outlook below analysts' estimates


Monday, 4 Aug 2014 08:30am EDT 

Ligand Pharmaceuticals Inc:Expects FY 2014 total revenues to be between $64 -$66 mln.Expects FY 2014 non-GAAP earnings per diluted share to be between $1.50 and $1.55.This is higher than previous guidance, which called for total revenues to be between $62 -$64 mln, and non-GAAP earnings per diluted share to be between $1.40 and $1.45.Expects Q3 2014 total revenues to be between $13 -$14 mln.Expects Q3 2014 non-GAAP earnings per diluted share to be between $0.26 and $0.29.FY 2014 revenue of $62 mln, EPS of $1.44 - Thomson Reuters I/B/E/S.Q3 2014 revenue of $16 mln, EPS of $0.40 - Thomson Reuters I/B/E/S. 

Company Quote

76.23
 --
30 Mar 2015